Background
==========

Oligodendrocytes are specialized cells of the central nervous system that produce myelin, a multilayered membrane spirally ensheathing axons and facilitating rapid nerve conduction \[[@B1],[@B2]\]. The development of oligodendrocytes is a gradual process, in which each step of the differentiation process is characterized by stage specific markers \[[@B3]-[@B6]\]. Oligodendrocytes originate from oligodendrocyte precursor cells that arise from multiple foci along the neuronal tube and migrate into the future white matter of the brain. After reaching their final position, they develop into mature post-mitotic cells that produce the myelin sheaths \[[@B7]\]. During the progression through the oligodendroglial lineage, the cells loose their migratory and proliferative capacities and undergo dramatic changes in their morphology by the formation of a highly branched network of processes. This transformation is accompanied by the expression of a number of gene products that are highly enriched or even specific to oligodendrocytes such as the myelin basic protein (MBP), proteolipid proteins (PLP/DM20), myelin-associated glycoprotein (MAG), cyclic nucleotide phosphodiesterase (CNP) and the glycolipids, galactosylceramide and sulfatide. The capacity of oligodendrocyte precursor cells to differentiate into oligodendrocytes that express these different gene products is intrinsic to the lineage and occurs even in the absence of neurons \[[@B4],[@B8]\]. Oligodendrocytes need to provide specific sorting and transport mechanisms to enable the synthesis of an extensive amount of myelin membrane in a very short time \[[@B3],[@B9]\]. Since oligodendrocytes must produce myelin at the appropriate time of neuronal development, a number of reciprocal signalling systems are likely to operate to coordinate the organisation of axonal domains and the biogenesis of myelin \[[@B10]-[@B15]\]. A number of recent studies have shown that neuronal-derived signalling molecules control the development of myelin-forming glial cells \[[@B16]-[@B21]\]. We have recently shown that neurons regulate membrane trafficking in oligodendrocytes \[[@B19]\]. In the absence of neurons, the major myelin protein, PLP, is internalized and stored in late endosomes. After receiving an unknown soluble signal from neurons, oligodendrocytes reduce the rate of endocytosis and increase the retrograde transport of PLP from late endosomes to the plasma membrane. A fraction of PLP is released in association with exosomes \[[@B22],[@B23]\]. Our previous work shows that changes in Rho GTPase activity were responsible for switching between these two modes of transport \[[@B24]\]. Inactivation of Rho GTPase activity reduced the transport of cargo to late endosomes and at the same time increased the mobilization of membrane from late endosomes. We found that a neuronal soluble factor was responsible for the downregulation of RhoA GTPase activity in the oligodendroglial cell line, Oli-neu \[[@B24]\]. The downregulation of RhoA function during morphological differentiation of oligodendrocytes is supported by a number of other studies \[[@B18],[@B25]\]. In this study, we were interested in the transcriptional changes that occur after differentiation of Oli-neu cells by conditioned neuronal medium or by inactivation of Rho GTPase function. This effort led to the identification of the transmembrane protein 10 (Tmem10/Opalin) as a novel marker for oligodendrocytes. The transmembrane protein 10 is known as Tmem10/TMEM10 in mice, rats and humans, with the synonyms TMP10 or HTMP10. Recently four Tmem10 homologs of prosimian species (*Eulemur macaco*, *Lemur catta*, *Microcebus murinus*and *Otolemur garnetti*) have been named Opalin \[[@B26]\]. In this work the human, rat and mouse transmembrane protein 10 will be referred to as Tmem10.

Results and Discussion
======================

As a cellular model for oligodendrocyte differentiation we use the oligodendroglial cell line, Oli-neu. The advantage of this system is that morphological differentiation of a pure oligodendroglial culture can be triggered synchronously by adding conditioned medium from primary neuronal cultures to the cells. To characterize the gene changes that occur after incubation of Oli-neu cells with conditioned neuronal medium, we used Affymetrix microarrays. Oli-neu cells were incubated for 16 hours with conditioned neuronal medium and compared to untreated parallel cultures. Cell fractions were used to purify mRNA for microarray analysis (the data is available at NCBI Geo accession number GSE10291). Using a 1.7 fold cut-off, we found that 716 genes were up-regulated, whereas 386 genes were down-regulated by conditioned neuronal medium as compared to the control. The eighty most highly induced genes are shown in Table [1](#T1){ref-type="table"}. We have previously shown that incubation of Oli-neu cells with conditioned neuronal medium leads to RhoA GTPase inactivation. We, therefore, performed gene expression profiling analysis after treating cells with the Rho kinase (ROCK) inhibitor, Y27632 for 16 hours and compared the transcriptional changes to the ones obtained after incubation with conditioned neuronal medium. Interestingly, 70% of the genes that were controlled by both conditioned neuronal medium and by treatment with Y27632 were regulated into the same direction, indicating that these treatments affected the fate of the cells into a common path (Table [2](#T2){ref-type="table"}). Some of these genes such as the UDP galactosyltransferase 8a and CNP are known to be upregulated during the progression through the oligodendroglial lineage \[[@B4]\], whereas known housekeeping genes such as the ATP synthase served as internal controls and were not differentially expressed after incubation with conditioned neuronal medium or Y27632 (data not shown). One so far not characterized, but highly upregulated gene is the brain-specifically expressed, Tmem10 \[[@B27]\]. For our further study, we decided to focus on Tmem10 for a number of reasons. Tmem10 was the strongest up-regulated gene in our analysis of transcriptional changes induced by conditioned neuronal medium and as well highly up-regulated after treatment with Y27632. The analysis of the average fold up-regulation in both conditions shows that Tmem10 is the most up-regulated gene together with Cyp2c39 (cytochrome P450, family2, polypeptide 39) (Table [3](#T3){ref-type="table"}). In addition, a previous microarray analysis identified a 23.75 fold up-regulation of Tmem10 during oligodendrocyte differentiation \[[@B28]\] and *in situ*expression data of Tmem10 in the Allen Brain Atlas <http://www.brain-map.org> suggested enrichment in the white matter of the brain.

###### 

Top 80 upregulated genes after addition of conditioned neuronal medium to Oli-neu cells

  Probe set ID    Fold change   p-value   Gene name                                                    Gene symbol
  --------------- ------------- --------- ------------------------------------------------------------ --------------------
  A_52_P624415    7.12          0.00015   transmembrane protein 10                                     Tmem10
  A_51_P225761    6.96          0.00020   ESTs, no homologies found                                    
  A_52_P225856    6.76          0.00013   ESTs, no homologies found                                    
  A_52_P329250    6.51          0.00000   chromodomain helicase DNA binding protein 1                  Chd1
  A_51_P304109    6.41          0.00007   cytochrome P450, family 2, subfamily c, polypeptide 39       Cyp2c39
  A_52_P160518    6.23          0.00005   Scm-like with four mbt domains 1                             Sfmbt1
  A_52_P771513    6.22          0.00027   ESTs, no homologies found                                    
  A_52_P61864     6.14          0.00023   wingless-related MMTV integration site 2                     Wnt2
  A_51_P370640    6.05          0.00013   zinc finger, CCHC domain containing 5                        Zcchc5
  A_51_P186092    6             0.00017   male sterility domain containing 2                           Mlstd2
  A_52_P24076     5.95          0.00026   myotubularin related protein 7                               Mtmr7
  A_52_P448870    5.9           0.00025   RAB26, member RAS oncogene family                            Rab26
  A_52_P193256    5.81          0.00032   DNA segment, Chr 10, Brigham & Women\'s Genetics 0791        D10Bwg0791e
  A_52_P350750    5.81          0.00017   cholinergic receptor, nicotinic, alpha polypeptide 4         Chrna4
  A_52_P391098    5.74          0.00022   cAMP responsive element modulator                            Crem
  A_51_P127035    5.72          0.00082   RIKEN cDNA 4432405B04 gene                                   4432405B04Rik
  A_52_P600304    5.69          0.00013   RIKEN cDNA 1200007B05 gene                                   1200007B05Rik
  A_51_P448632    5.68          0.00033   RIKEN cDNA C030022K24 gene                                   C030022K24Rik
  A_52_P188593    5.68          0.00017   hypothetical gene supported by AK049058; BC025881            LOC433886
  A_51_P359002    5.59          0.00028   ESTs, no homologies found                                    
  A_52_P302587    5.55          0.00021   chimerin (chimaerin) 2                                       Chn2
  A_51_P444502    5.44          0.00029   immunoglobulin kappa light chain variable region Vk23        LOC381783
  A_51_P461404    5.42          0.00014   SWI/SNF related, actin dependent regulator of chromatin      Smarca1
  A_52_P577329    5.37          0.00021   RIKEN cDNA A230069A22 gene                                   A230069A22Rik
  A_51_P334449    5.37          0.00033   olfactory receptor 50                                        Olfr50
  A_52_P354306    5.32          0.00013   peroxisome biogenesis factor 26                              Pex26
  A_51_P462978    5.31          0.00033   membrane protein, palmitoylated 2                            Mpp2
  A_52_P661972    5.3           0.00021   RIKEN cDNA 9230112E08 gene                                   9230112E08Rik
  A_52_P1133703   5.29          0.00014   CD47 antigen (Rh-related antigen)                            Cd47
  A_51_P169617    5.28          0.00041   TAF3 RNA polymerase II, TATA box binding protein             Taf3
  A_51_P339934    5.24          0.00022   neurofilament, light polypeptide                             Nefl
  A_51_P472113    5.23          0.00060   ESTs, no homologies found                                    
  A_51_P262563    5.22          0.00031   ESTs, no homologies found                                    
  A_51_P284486    5.2           0.00030   glutathione S-transferase, mu 2                              Gstm2
  A_51_P103706    5.17          0.00054   cytochrome P450, family 2, subfamily c, polypeptide 29       Cyp2c29
  A_52_P223626    5.17          0.00011   oligodendrocyte transcription factor 2                       Olig2
  A_51_P392209    5.17          0.00019   zinc finger protein 482                                      Zfp482
  A_51_P283499    5.17          0.00022   dopamine receptor 4                                          Drd4
  A_52_P229052    5.17          0.00019   transmembrane prot. with EGF-like and two follistatin-like   Tmeff2
  A_52_P337910    5.15          0.00015   RIKEN cDNA E130114P18 gene                                   E130114P18Rik
  A_51_P129108    5.11          0.00019   activating transcription factor 6                            Atf6
  A_51_P393934    5.11          0.00028   CD82 antigen                                                 Cd82
  A_51_P413005    5.08          0.00021   chimerin (chimaerin) 2                                       Chn2
  A_51_P394574    5.05          0.00019   ESTs, no homologies found                                    
  A_51_P478003    5.04          0.00046   poly(A) polymerase gamma                                     Papolg
  A_52_P516733    5.02          0.00086   DNA segment, Chr 15, ERATO Doi 621, expressed                D15Ertd621e
  A_52_P127776    5.01          0.00030   ESTs, no homologies found                                    
  A_52_P384479    4.95          0.00014   leucine rich repeat and fibronectin type III domain          Lrfn5
  A_52_P118323    4.93          0.00042   ESTs, no homologies found                                    
  A_52_P685963    4.91          0.00041   tenascin R                                                   Tnr
  A_52_P313068    4.83          0.00016   RIKEN cDNA 8030462N17 gene                                   8030462N17Rik
  A_51_P489107    4.83          0.00013   pleckstrin homology domain-containing, family A, memb. 2     Plekha2
  A_51_P454008    4.82          0.00027   lipopolysaccharide binding protein                           Lbp
  A_52_P418956    4.81          0.00059   RIKEN cDNA 4933431E20 gene                                   4933431E20Rik
  A_51_P244453    4.8           0.00059   potassium channel tetramerisation domain containing 3        Kctd3
  A_51_P342206    4.79          0.00890   cytochrome P450, family 2, subfamily c, polypeptide 38       Cyp2c38
  A_51_P270899    4.78          0.00019   zinc finger protein 61                                       Zfp61
  A_52_P370162    4.78          0.00034   G protein-coupled receptor 23                                Gpr23
  A_52_P356170    4.77          0.00024   glyceraldehyde-3-phosphate dehydrogenase, spermatogenic      Gapdhs
  A_51_P130254    4.75          0.00021   pleckstrin and Sec7 domain containing 3                      Psd3
  A_51_P363461    4.73          0.00022   ESTs, no homologies found                                    
  A_52_P502838    4.72          0.00033   mannoside acetylglucosaminyltransferase 5                    Mgat5
  A_51_P494122    4.69          0.00050   RIKEN cDNA 1810009K13 gene                                   1810009K13Rik
  A_52_P285194    4.69          0.00021   ESTs, no homologies found                                    
  A_51_P169087    4.67          0.00035   ESTs, no homologies found                                    
  A_51_P506822    4.65          0.00015   UDP galactosyltransferase 8A                                 Ugt8a
  A_52_P164709    4.64          0.00030   WD repeat domain 51A                                         Wdr51a
  A_51_P226269    4.62          0.00022   RIKEN cDNA 1190002H23 gene                                   1190002H23Rik
  r60_a9          4.55          0.00003   fibronectin 1                                                Fn1
  A_51_P111233    4.49          0.00013   dopamine receptor 2                                          Drd2
  A_52_P265556    4.49          0.00042   predicted gene, ENSMUSG00000056850                           ENSMUSG00000056850
  A_52_P417654    4.47          0.00022   transcription elongation factor A (SII) 1                    Tcea1
  A_52_P625249    4.44          0.00021   cytochrome P450, family 2. subfamily c, polypeptide 37       Cyp2c37
  A_52_P603038    4.44          0.00021   oligodendrocyte transcription factor 1                       Olig1
  A_51_P199199    4.42          0.00024   phosphoinositide-3-kinase adaptor protein 1                  Pik3ap1
  A_52_P510706    4.41          0.00030   DnaJ (Hsp40) homolog, subfamily A, member 2                  Dnaja2
  A_52_P57416     4.39          0.00044   ESTs, no homologies found                                    
  A_52_P322639    4.38          0.00031   ESTs, no homologies found                                    
  A_51_P232901    4.37          0.00007   cyclic nucleotide phosphodiesterase 1                        Cnp1

###### 

Genes regulated in the same direction after treatment with conditioned neuronal medium (cnm) or Y27632

                 **Cnm**   **Y27632**                                                                                
  -------------- --------- ------------ ------- --------- ---------------------------------------------------------- ------------------
  A_52_P624415   7,12      0,00015      2,2     0,00054   transmembrane protein 10                                   Tmem10
  A_51_P304109   6,41      0,00007      2,96    0,00127   cytochrome P450, family 2, subfamily c, polypept. 39       Cyp2c39
  A_52_P302587   5,55      0,00021      1,48    0,00111   chimerin (chimaerin) 2                                     Chn2
  A_52_P229052   5,17      0,00019      2,05    0,00067   transmembr. prot. with EGF-like, dom. 2                    Tmeff2
  A_51_P103706   5,17      0,00054      1,29    0,00429   cytochrome P450, family 2, subfamily c, polypept. 29       Cyp2c29
  A_51_P413005   5,08      0,00021      1,43    0,00086   chimerin (chimaerin) 2                                     Chn2
  A_51_P454008   4,82      0,00027      1,37    0,00043   lipopolysaccharide binding protein                         Lbp
  A_51_P506822   4,65      0,00015      1,25    0,00296   UDP galactosyltransferase 8A                               Ugt8a
  A_51_P232901   4,37      0,00007      1,47    0,00096   cyclic nucleotide phosphodiesterase 1                      Cnp1
  A_52_P661327   4,31      0,00018      1,3     0,00029   phytanoyl-CoA hydroxylase interacting protein-like         Phyhipl
  A_51_P433194   3,43      0,00024      1,46    0,00218   breast carcinoma amplified sequence 1                      Bcas1
  A_51_P437079   3,07      0,00013      1,44    0,00068   RIKEN cDNA 5730559C18 gene                                 5730559C18Rik
  A_52_P269003   2,53      0,00062      1,45    0,00147   Neogenin                                                   Neo1
  A_51_P259975   2,48      0,00007      1,54    0,00051   aspartoacylase                                             Aspa
  A_52_P493854   2,42      0,0002       2,18    0,00084   potassium channel tetramerisation domain                   Kctd4
  A_52_P493857   2,39      0,00023      2,31    0,00111   potassium channel tetramerisation domain                   Kctd4
  A_51_P354354   2,29      0,00032      2,12    0,00172   galactose-3-O-sulfotransferase 1                           Gal3st1
  A_51_P112308   2,25      0,00014      1,26    0,00057   RIKEN cDNA 1810011O10 gene                                 1810011O10Rik
  A_51_P413721   2,18      0,00025      1,88    0,00036   gap junction membrane channel prot. epsilon 1              Gje1
  A_51_P145376   2,12      0,00024      1,48    0,00033   OTU domain containing 7B                                   Otud7b
  A_52_P168953   2,07      0,00037      1,38    0,0073    Versican                                                   Vcan
  A_52_P376169   2         0,00016      1,23    0,00125   LY6/PLAUR domain containing 6                              Lypd6
  A_51_P196596   1,95      0,00022      2,42    0,00046   tripartite motif protein 2                                 Trim2
  A_51_P159453   1,94      0,00026      1,68    0,00202   serine (or cystein) peptidase inhib. 3n                    Serpina3n
  A_52_P149801   1,92      0,00044      1,9     0,0007    phosphodiesterase 4B, cAMP specific                        Pde4b
  A_52_P121502   1,87      0,00045      1,34    0,00159   plasma membrane proteolipid                                Pllp
  A_52_P465012   1,76      0,00081      2,75    0,00029   protein phosphatase 2, SU B (PR 52), beta isoform          Ppp2r2b
  A_51_P512119   1,73      0,00067      1,31    0,00255   cDNA sequence AF067063                                     AF067063
                                                                                                                     
  A_52_P213932   -4,18     0,00021      -1,85   0,00255   metallopeptidase with thrombospondin type 1                Adamts1
  A_51_P426754   -4,17     0,00203      -2,89   0,00059   annexin A5                                                 Anxa5
  A_52_P520495   -4,09     0,00022      -3,34   0,0005    vascular cell adhesion molecule 1                          Vcam1
  A_51_P115462   -3,73     0,00027      -2,57   0,00091   spermatogen. associat. glut. (E)-rich prot. 6, ps 1        Speer6-ps1
  A_52_P433119   -3,55     0,00313      -2,14   0,00092   spermatogenesis associat. glut. (E)-rich prot. 2           Speer2
  A_51_P183571   -3,31     0,00022      -1,64   0,0013    serine (or cysteine) peptidase inhib. 1                    Serpine1
  A_52_P62037    -3,18     0,00032      -1,47   0,00052   annexin A2                                                 Anxa2
  A_52_P63948    -3,13     0,0002       -2,44   0,00058   cDNA sequence BC048651                                     BC048651
  A_52_P148703   -3,09     0,00013      -1,66   0,00059   fer-1-like 3, myoferlin (C. elegans)                       Fer1l3
  A_51_P131408   -2,99     0,00014      -1,33   0,00168   tumor necrosis factor receptor superfamily,12a             Tnfrsf12a
  A_51_P282584   -2,96     0,0002       -1,39   0,00137   Olfactomedin-like 2B                                       Olfml2b
  A_51_P165342   -2,87     0,00035      -1,84   0,00135   annexin A2                                                 Anxa2
  A_52_P518949   -2,84     0,00044      -2,3    0,00035   similar to spermatogen. associat. glut. (E)-rich prot. 2   LOC381612
  A_52_P771912   -2,84     0,00019      -2,18   0,00091   lymphocyte antigen 6 complex, locus C                      Ly6c
  A_52_P360440   -2,81     0,00063      -1,39   0,00052   fer-1-like 3, myoferlin (C. elegans)                       Fer1l3
  A_51_P182116   -2,79     0,00021      -2,97   0,00033   Down syndrome critical region homolog 1 (human)            Dscr1
  A_52_P628885   -2,77     0,00027      -2,25   0,00072   brain and acute leukemia, cytoplasmic                      Baalc
  A_52_P385546   -2,64     0,0002       -1,32   0,00158   C1q-like 3                                                 C1ql3
  A_52_P594584   -2,59     0,00179      -2,09   0,00208   spermatogenesis associat. glut. (E)-rich protein 2         Speer2
  A_51_P228472   -2,48     0,00028      -1,94   0,00069   insulin-like growth factor binding protein 3               Igfbp3
  A_52_P196732   -2,43     0,00039      -1,57   0,00151   NIMA-related expressed kinase 6                            Nek6
  A_51_P181595   -2,38     0,00024      -1,77   0,00058   spermatogen. associat. glut. (E)-rich prot. 1, ps 1        Speer1-ps1
  A_51_P435023   -2,37     0,00007      -1,44   0,0003    Ras association (RalGDS/AF-6) domain family 1              Rassf1
  A_52_P661565   -2,36     0,00034      -3,42   0,00068   chloride intracellular channel 4 (mitochondrial)           Clic4
  A_52_P230938   -2,34     0,00082      -2,02   0,00771   lymphocyte antigen 6 complex, locus C                      Ly6c
  A_52_P93256    -2,25     0,00047      -1,49   0,00054   angiopoietin-like 2                                        Angptl2
  A_51_P384968   -2,18     0,00046      -1,34   0,00158   nerve growth factor recept. (TNFR superfam., m16)          Ngfr
  A_52_P427640   -2,14     0,00009      -1,84   0,00035   serine (or cysteine) proteinase inhib. 3m                  Serpina3m
  A_51_P351896   -2,08     0,00022      -1,29   0,00214   RIKEN cDNA 1110032E23 gene                                 1110032E23Rik
  A_51_P427663   -2,08     0,00022      -1,61   0,00043   calponin 2                                                 Cnn2
  A_51_P248441   -2,07     0,00061      -1,23   0,00047   ubiquitin-conjugating enzyme E2G 2                         Ube2g2
  A_51_P344263   -2,01     0,00079      -1,47   0,00115   brain and acute leukemia, cytoplasmic                      Baalc
  A_51_P411253   -2        0,00014      -1,73   0,00062   phosphoprotein enriched in astrocytes 15A                  Pea15a
  A_52_P201206   -2        0,00022      -1,31   0,00102   secernin 1                                                 Scrn1
  A_51_P517843   -1,94     0,00697      -1,43   0,00125   GLI pathogenesis-related 2                                 Glipr2
  A_51_P503162   -1,9      0,00064      -1,48   0,00099   Kruppel-like factor 6                                      Klf6
  A_52_P359088   -1,9      0,00704      -1,4    0,00314   solute carrier family 25 (mitochond., phosphat.)           Slc25a25
  A_52_P617327   -1,76     0,00042      -1,54   0,00049   Down syndrome critical region homolog 1 (human)            Dscr1
  A_52_P403157   -1,73     0,00131      -4,01   0,00029   sorbin and SH3 domain containing 2                         Sorbs2
  A_52_P246698   -1,72     0,00036      -1,6    0,00091   down-regulated by Ctnnb1, a                                Drctnnb1a
  A_51_P103819   -1,71     0,00173      -1,2    0,00036   similar to Tribbles homolog 2 (predicted)                  RGD1564451_pred.

###### 

Top 10 up-regulated genes co-regulated after treatment with conditioned neuronal medium (cnm) or ROCK inhibitor (Y27632)

                 **cnm**   **Y27632**   **(cnm+Y27632)/2**                                                          
  -------------- --------- ------------ -------------------- ------------------------------------------------------ ---------
  A_52_P624415   7,12      2,2          **4,7**              transmembrane protein 10                               Tmem10
  A_51_P304109   6,41      2,96         **4,7**              cytochrome P450, family 2, subfamily c, polypept. 39   Cyp2c39
  A_52_P302587   5,55      1,48         **3,5**              chimerin (chimaerin) 2                                 Chn2
  A_52_P229052   5,17      2,05         **3,6**              transmembr. prot. with EGF-like, dom. 2                Tmeff2
  A_51_P103706   5,17      1,29         **3,2**              cytochrome P450, family 2, subfamily c, polypept. 29   Cyp2c29
  A_51_P413005   5,08      1,43         **3,3**              chimerin (chimaerin) 2                                 Chn2
  A_51_P454008   4,82      1,37         **3,1**              lipopolysaccharide binding protein                     Lbp
  A_51_P506822   4,65      1,25         **3,0**              UDP galactosyltransferase 8A                           Ugt8a
  A_51_P232901   4,37      1,47         **2,9**              cyclic nucleotide phosphodiesterase 1                  Cnp1
  A_52_P661327   4,31      1,3          **2,8**              phytanoyl-CoA hydroxylase interacting protein-like     Phyhipl

To begin our characterization of Tmem10 we raised an antibody against the C-terminal part of the protein and performed immunofluorescence analysis on primary cultures of oligodendrocytes. We did not detect Tmem10 on NG2-positive oligodendrocyte precursor cells, whereas pre-oligodendrocytes that were still NG2-positive, but also contained O4 started to express Tmem10 (Fig [1A, B](#F1){ref-type="fig"}). Higher expression of Tmem10 was identified on NG2-negative and O4-positive or O1-positive oligodendrocytes (Fig [1A, C](#F1){ref-type="fig"}). Low levels of Tmem10 expression can be detected in A2B5-positive oligodendrocyte progenitors (Fig [1D](#F1){ref-type="fig"}). Colocalization studies of Tmem10 with MBP indicated that Tmem10 was present in mature oligodendrocytes where it was enriched in the rims and processes of the cells and was found only to a lesser extent in the membrane sheets (Fig. [1E](#F1){ref-type="fig"}). Comparisons of Tmem10 expression in O4-positive/MBP-negative and MBP-positive cells shows that Tmem10 is redistributed to the rims of the membrane sheets, but the expression level does not change significantly compared to O4-positive oligodendrocytes (Fig [1B](#F1){ref-type="fig"}).

![**Tmem10 is expressed during oligodendrocyte differentiation**. **(A)**Primary oligodendrocytes were cultured for 2--3 days and levels of Tmem10 (green) expression were determined by immunofluorescence. The developmental stage of the cells was determined by costaining for NG2 (red) or O4 (blue). **(B)**Quantitative analysis of the Tmem10 immunofluorescence intensities. Values represent the mean ± SEM (n \> 20 cells, \*\*\*p \< 0,001). **(C)**Tmem10 (green) is expressed in O1 (red) positive oligodendrocytes (day 2) and **(D)**Tmem10 (green) is weakly expressed in A2B5 (red) positive cells (day 2). **(E)**Tmem10 (green) localizes to processes and rims of mature oligodendrocytes, expressing MBP (red) (day 5). Scale bars, 10 μm.](1471-2202-9-40-1){#F1}

Interestingly, double labelling of Tmem10 with GFAP or neuron specific βIII Tubulin showed that Tmem10 could not be detected on GFAP-positive astrocytes or neurons, which are present as a minor cell population in the same cultures, indicating a specific expression of Tmem10 in differentiating oligodendrocytes (Fig. [2A, B](#F2){ref-type="fig"}). Additionally, we analysed primary cultures of astrocytes and microglia cultures, but could not detect Tmem10 on either of these cell types (Fig. [2C, D](#F2){ref-type="fig"}).

![**Tmem10 is not detected on neurons, astrocytes and microglia**. **(A)**Tmem10 (red) is specifically expressed in oligodendrocytes, but absent form GFAP-positive astrocytes (GFAP, green). **(B)**Tmem10 (green) is enriched in oligodendrocytes, labelled with O4 (blue) compared to neurons stained for neuronal βIII Tubulin (red). Tmem10 (green) is not detectable on **(C)**astrocytes (GFAP, red) and **(D)**microglia (stained with isolectin IB~4~conjugated to Alexa Fluor 568, red) in cultures enriched for these cells types. Scale bars, 10 μm.](1471-2202-9-40-2){#F2}

The analysis of the primary amino acid sequence of Tmem10 for protein domains and functional sites with InterProScan \[[@B29]\] revealed a predicted signal peptide (amino acid 1--15 in the mouse sequence) and a putative transmembrane domain (amino acid 31--51 in the mouse sequence) (Fig. [3A](#F3){ref-type="fig"}). To further characterize the protein structure and the membrane orientation of Tmem10, we used N-terminal ECFP- and C-terminal EYFP-fusion proteins of Tmem10. Oli-neu cells were transfected with either of the fusion proteins and live staining was performed at 4°C with anti-GFP antibody to specifically label the proteins at the cell surface. We found that only the N-terminal ECFP-fusion protein was detectable by surface staining, whereas premeabilization of the cells uncovered both fusion proteins (Fig. [3B](#F3){ref-type="fig"}). These results show that Tmem10, as predicted from its primary amino acid sequence, is a type I membrane protein.

![**Tmem10 is a type I transmembrane protein**. **(A)**Alignment of mouse, rat and human Tmem10 amino acid sequence. Black/grey box indicates the predicted position of the transmembrane domain. **(B)**Oli-neu cells were transfected to express either N-terminal ECFP-tagged or C-terminal EYFP-tagged Tmem10. Subsequent staining with anti-GFP antibody was performed either on living, unpermeabilized (surface anti-GFP) or on fixed, permeabilized (after permeabilization anti-GFP) cells. Scale bars, 10 μm.](1471-2202-9-40-3){#F3}

After ectopic expression of both Tmem10 fusion proteins and an untagged expression construct, we found that it was mainly localized at the plasma membrane with only very little intracellular staining. Tmem10 appeared to be enriched in actin-rich membrane ruffles at the cell surface as shown by its colocalization with rhodamine-phalloidin (Fig [4A](#F4){ref-type="fig"}). Additionally, comparison of Tmem10 transfected Oli-neu with untransfected control cells shows that our anti-Tmem10 antibody specifically recognizes Tmem10 (Fig [4A](#F4){ref-type="fig"}).

![**Tmem10 colocalizes with actin in processes and membrane ruffles**. **(A)**Oli-neu cells were transfected with a plasmid encoding for rat Tmem10 and subsequently stained for Tmem10 (green) and Actin (red) with rhodamin-labelled phalloidin. Note the colocalization of Tmem10 with Actin in processes and membrane ruffles. The absence of Tmem10 labelling in untransfected cells shows the specificity of the generated anti-Tmem10 antiserum. **(B, C)**Oli-neu cells were transfected with Tmem10-EYFP and treated with 2 μM latrunculin A for 30 min 16 h after transfection. **(B)**FRAP was measured by bleaching a squared region of interest within the cell body and fluorescence recovery in this regions was examined. Average FRAP tracings for 15 cells form 2 independent experiments are shown. **(C)**Tmem10-EYFP (green) accumulates in intracellular sites (arrow head) after disruption of the F-actin (red) cytoskeleton with latrunculin A. Scale bar, 10 μm.](1471-2202-9-40-4){#F4}

To investigate the role of the actin cytoskeleton on the lateral mobility of Tmem10 we performed fluorescence recovery after photobleaching (FRAP) experiments in the presence or absence of the F-actin disrupting drug, latrunculin A. The mobile fraction and the half time of fluorescence recovery did not change after treatment with latrunculin A (Fig [4B](#F4){ref-type="fig"}), indicating that the lateral mobility of Tmem10 within the plasma membrane is not dependent on a functional cortical actin cytoskeleton. Interestingly, we did observe a redistribution of a fraction of plasma membrane Tmem10 into intracellular sites after treatment with latrunculin A (Fig [4C](#F4){ref-type="fig"}), suggesting a role of the actin cytoskeleton in keeping Tmem10 at the cell surface.

In summary, we have applied an expression profiling approach to identify genes upregulated during Oli-neu cell differentiation. We used two different experimental approaches -- incubation with conditioned neuronal medium or treatment with the Rho kinase (ROCK) inhibitor, Y-27632. This procedure led to the identification of Tmem10, a protein that appears during oligodendrocyte differentiation. In cultured oligodendrocytes, Tmem10 was absent from bipolar precursor cells and started to be expressed after the cells had acquired the O4 epitope.

A previous comparative genome analysis suggested that Tmem10 is a mammalian-specific gene \[[@B26]\]. Interestingly, the comparison of the genome structure of the Tmem10 gene and its flanking region identified an evolutionary conserved region within the first intron that functions as an oligodendrocyte-specific enhancer. This domain contains binding sites for Myt1 and cAMP-response element binding protein (CREB) and the treatment of Oli-neu cells with cAMP enhanced the expression of Tmem10 \[[@B26]\]. Previous studies have already shown that cAMP regulates the expression of several other oligodendroglial-specific genes \[[@B30]\], suggesting a general role for cAMP dependent signalling in the differentiation of oligodendrocytes into myelin-forming cells. Another factor that appears to regulate Tmem10 gene expression was the leukaemia inhibitory factor (LIF) \[[@B26]\], which seems to be released by astrocytes in response to ATP secreted by neurons and to promote myelination by mature oligodendrocytes \[[@B31]\]. Together, these data suggest a function for Tmem10 in an oligodendroglial specific process. Our finding that Tmem10 colocalizes with F-actin in plasma membrane ruffles and in F-actin-rich processes, points to a role in the regulation of the oligodendroglial actin cytoskeleton. This is reminiscent to another oligodendroglial-specific protein, Ermin, which has been implicated in the regulation of cell morphology by modulating the actin cytoskeleton \[[@B32]\]. The localization of Tmem10 to the leading edge of myelin sheets in mature oligodendrocytes suggests a role for Tmem10 in myelin membrane sheet extension. As Tmem10 localizes to the growing tip of the myelin sheet it could also be involved in the process of recognition or adhesion to potential axonal targets. Further analysis will be required to elucidate these issues.

Conclusion
==========

During the development of the nervous system oligodendrocytes form a highly branched network of processes and several oligodendroglial-specific genes such as Ermin, CNP and Tmem10 are expressed during this process. Gene profiling using microarrays is a useful starting point to identify genes relevant to oligodendrocyte differentiation and myelination \[[@B28],[@B33],[@B34]\]. Functional analysis of these proteins, as performed for CNP \[[@B35]\], will be required to elucidate their exact biological function in the generation of myelin-forming processes.

Methods
=======

Cell culture, transfections and immunofluorescence
--------------------------------------------------

Primary cultures of mouse oligodendrocytes were prepared as described previously \[[@B36]\]. In brief, cells were plated in MEM containing B27 supplement, 1% horse serum, L-thyroxine, tri-iodo-thyronine, glucose, glutamine, gentamycine, pyruvate, and bicarbonate on poly-L-lysine coated glass-coverslips after shaking. The minor population of neurons and astrocytes which arise together with the oligodendrocytes in the mixed brain cultures were used to assess Tmem10 expression in other cell types. Primary cultures of microglia and astrocytes were prepared as described previously \[[@B37]\]. In brief, microglial cells were shaken off, centrifuged and plated on poly-L-lysine coated coverslips in D-MEM containing 10% FCS, glutamine, penicillin and streptomycin. The remaining astrocytes were trypsinized, centrifuged and plated on poly-L-lysine coated coverslips in D-MEM containing 10% FCS, glutamine, penicillin and streptomycin. The oligodendroglial cell line Oli-neu was cultured as described previously \[[@B38]\]. For microarray experiments we used Oli-neu cells stably expressing PLP-EGFP \[[@B19]\]. Cells were treated for 16 h with conditioned neuronal medium or Y27632 (Calbiochem). Conditioned neuronal medium was obtained from primary cultures enriched in neurons after culturing for 2 weeks and used directly as described previously \[[@B24]\]. Transient transfections were performed using FuGENE transfection reagent (Roche Diagnostics, Basel, Switzerland) according to the manufacturer\'s protocol. Immunofluorescence was performed as described previously \[[@B19]\]. For surface labelling of ECFP-Tmem10 or Tmem10-EYFP transfected, living cells were incubated with anti-GFP antibody in medium for 10 min at 4°C, washed, fixed and labelled with secondary antibody. Disruption of the actin cytoskeleton was done 16 h after transfection with 2 μM latrunculin A for 30 min at 37°C.

Antibodies and plasmids
-----------------------

The following plasmids were used: human Tmem10 cDNA C-terminally fused with EYFP or N-terminally fused with ECFP \[[@B39]\] generated from modified pECFP-C1 or pEYFP-N1 expression vectors (Clonetech, Heidelberg, Germany), rat Tmem10 cDNA subcloned in pExpress-1 expression vector purchased form RZPD (Deutsches Ressourcenzentrum für Genomforschung GmbH, Berlin, Germany).

Anti-Tmem10 antiserum was induced in rabbits against the C-terminal Tmem10 sequence LERRRGLWWLVPSLSLE and the affinity purified IgG fraction was used. Peptid synthesis, immunization of the rabbit and affinity purification was carried out by Davids Biotechnology (Regensburg, Germany). Further the following primary antibodies were used: A2B5 (mouse monoclonal IgM, Chemicon (Millipore)), GFAP (mouse monoclonal IgG1; Vision BioSystems Novocastra, New Castle upon Tyne, UK), GFP (rabbit polyclonal IgG; Abcam, Cambridge, UK), MBP (mouse monoclonal IgG1; Sternberger Inc., Lutherville, MD), NG2 (rat IgG) \[[@B40]\], O1 (monoclonal IgM) \[[@B41]\], O4 (monoclonal IgM) \[[@B41]\], Tmem10 (rabbit polyclonal IgG fraction), neuron specific βIII Tubulin (mouse monoclonal IgG1; Promega, Madison, WI). Microglial cells were stained with isolectin IB~4~conjugated to Alexa Fluor 568 from Molecular Probes (Invitrogen, Carlsbad, CA). Secondary antibodies were purchased from Dianova (Hamburg, Germany) and rhodamin-labelled phalloidin from Molecular Probes (Invitrogen, Carlsbad, CA).

RNA isolation
-------------

RNA isolation was performed using the Trizol (Invitrogen, Carlsbad, CA) method according to the manufacturer\'s recommendations and stored at -80°C. Afterwards, the samples were DNAse I treated in order to remove genomic DNA contaminations. RNA quality was determined using the Agilent 2100 Bioanalyzer (Agilent Technologies) microfluidic electrophoresis. Only sample pairs with comparable RNA integrity numbers were selected for microarray analysis.

Experimental design and sample preparation for 2 colour-microarrays
-------------------------------------------------------------------

For gene expression profiling, a two-colour 1 × 2 design including a dye swap using 6 arrays was applied, comparing Oli-neu cells stably expressing PLP-EGFP treated for 16 h with conditioned neuronal medium or Y27632, respectively, to untreated parallel cultures.

The samples for hybridization were prepared from total RNA according to the Atlas SMART Fluorescent Probe Amplification Kit (Clonetech-Takara Bio Europe) protocol, except, that the RNA template was hydrolyzed under alkaline conditions before cDNA purification, and the PCR amplification process was monitored and stopped in the exponential phase. Quantity and Cy-dye incorporation rates of the generated target material were assessed using a NanoDrop ND-100. Cy3- and Cy5-labelled cDNA fragments, respectively, were hybridized to Agilent Technologies 44 K Mouse Whole Genome Microarrays (G4112A) for 17 h at 65°C. Post-processing washes were done according to the Agilent Technologies SSPE protocol (v2.1), replacing wash solution 3 by acetonitril, followed by immediate scanning using an Agilent G2505B scanner. Intensity data were extracted using the software \'Automatic Image processing for Microarrays\'.

Statistical analysis
--------------------

Normalization of the raw intensity data was done with a non-linear loess regression \[[@B42]\].

Uni- and multivariate designs
-----------------------------

Differentially expressed genes were identified by an ANOVA fixed effects model \[[@B43]\]. The resulting P-values were adjusted with the Benjamini-Hochberg method to control the False-Discovery-Rate \[[@B44]\]. Normalization and statistical computation was done for two independent datasets derived from a high gain and a low gain scan, allowing replacement of saturated features in the high gain scan with data from the low gain measurement.

Sequence analysis
-----------------

The prediction of the transmembrane domain of Tmem10 was done using the InterProScan algorithm provided at EMBL-EBI \[[@B29]\].

Microscopy and analysis
-----------------------

Fluorescence images were acquired on a confocal laser scanning microscope (TCS SP equipped with AOBS, Leica) with a 40× or 63× oil plan-apochromat objective (Leica). Image processing and analysis was performed using Meta Imaging Series 6.1 software (Universal Imaging Corporation). Quantification of fluorescence intensities was performed as described previously \[[@B19]\]. FRAP experiments were done as described in \[[@B20]\].
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